In addition, pirfenidone, a TGF-β1 inhibitor, has shown beneficial effects by reducing ventricular tachycardia rates, attenuating myocardial infarct size, and decreasing cardiac fibrosis area [162]. The gene discussed is TGFB1; the disease is myocardial infarction.